Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Swedish Orphan Biovitrum AB ( (SE:SOBI) ) has issued an announcement.
Sobi reported positive topline results from its pivotal Phase 3 REDUCE 2 trial of pozdeutinurad, a once-daily oral URAT1 inhibitor for adults with gout, including those inadequately controlled by existing therapies. Both 50 mg and 75 mg doses met the primary endpoint of achieving serum uric acid below 6 mg/dL at six months versus placebo, with a safety profile in line with earlier studies, supporting the drug’s potential as a new option for uncontrolled and tophaceous gout.
The data strengthen Sobi’s strategic expansion in gout following its acquisition of Arthrosi, Inc. in 2026, adding a late-stage asset to its rare-disease-focused portfolio. Pozdeutinurad is being evaluated in two large global Phase 3 trials, each enrolling more than 800 patients, and the REDUCE 2 outcome underpins forthcoming regulatory submissions and could improve long-term outcomes for patients who fail first-line urate-lowering therapies.
The most recent analyst rating on (SE:SOBI) stock is a Buy with a SEK530.00 price target. To see the full list of analyst forecasts on Swedish Orphan Biovitrum AB stock, see the SE:SOBI Stock Forecast page.
More about Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB, or Sobi, is a global biopharmaceutical company focused on breakthrough treatments for rare diseases, with a growing presence in gout. Headquartered in Stockholm and listed on Nasdaq Stockholm, the company generated SEK 28 billion in revenue in 2025 and employs about 2,000 people across Europe, North America, the Middle East, Asia and Australia.
Average Trading Volume: 396,832
Technical Sentiment Signal: Buy
Current Market Cap: SEK150.5B
Learn more about SOBI stock on TipRanks’ Stock Analysis page.